Switch theme
Sign up to access all valuation multiples
Laboratorio Farmaceutico Erfo SpA operates in the nutraceutical sector. The company specializes in formulating and producing food supplements and natural medicines in different forms such as liquids, powders, granules, tablets, and soft gels. Geographically, the company generates a majority of its revenue from Italy followed by Spain, France, Belgium, and other countries.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Laboratorio Farmaceutico has a last 12-month revenue (LTM) of $9.6M and a last 12-month EBITDA of $2.2M.
In the most recent fiscal year, Laboratorio Farmaceutico achieved revenue of $7.0M and an EBITDA of $1.8M.
Laboratorio Farmaceutico expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Laboratorio Farmaceutico valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.6M | XXX | $7.0M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $3.1M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $2.2M | XXX | $1.8M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $1.2M | XXX | $1.1M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $0.7M | XXX | $0.7M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 30, 2025, Laboratorio Farmaceutico's stock price is EUR 1 (or $2).
Laboratorio Farmaceutico has current market cap of EUR 10.9M (or $12.8M), and EV of EUR 11.0M (or $12.9M).
See Laboratorio Farmaceutico trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.9M | $12.8M | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 30, 2025, Laboratorio Farmaceutico has market cap of $12.8M and EV of $12.9M.
Laboratorio Farmaceutico's trades at 1.9x EV/Revenue multiple, and 7.0x EV/EBITDA.
Equity research analysts estimate Laboratorio Farmaceutico's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Laboratorio Farmaceutico has a P/E ratio of 19.0x.
See valuation multiples for Laboratorio Farmaceutico and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.8M | XXX | $12.8M | XXX | XXX | XXX |
| EV (current) | $12.9M | XXX | $12.9M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 5.9x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBIT | 10.8x | XXX | 12.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.0x | XXX | 19.7x | XXX | XXX | XXX |
| EV/FCF | -2360.2x | XXX | -74.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLaboratorio Farmaceutico's last 12 month revenue growth is 25%
Laboratorio Farmaceutico's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Laboratorio Farmaceutico's rule of 40 is 60% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Laboratorio Farmaceutico's rule of X is 86% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Laboratorio Farmaceutico and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 60% | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 86% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Agthia Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Acomo | XXX | XXX | XXX | XXX | XXX | XXX |
| ForFarmers | XXX | XXX | XXX | XXX | XXX | XXX |
| JDE Peets | XXX | XXX | XXX | XXX | XXX | XXX |
| Sligro Food Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laboratorio Farmaceutico acquired XXX companies to date.
Last acquisition by Laboratorio Farmaceutico was XXXXXXXX, XXXXX XXXXX XXXXXX . Laboratorio Farmaceutico acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Laboratorio Farmaceutico headquartered? | Laboratorio Farmaceutico is headquartered in Italy. |
| How many employees does Laboratorio Farmaceutico have? | As of today, Laboratorio Farmaceutico has 33 employees. |
| Is Laboratorio Farmaceutico publicy listed? | Yes, Laboratorio Farmaceutico is a public company listed on MIL. |
| What is the stock symbol of Laboratorio Farmaceutico? | Laboratorio Farmaceutico trades under ERFO ticker. |
| When did Laboratorio Farmaceutico go public? | Laboratorio Farmaceutico went public in 2022. |
| Who are competitors of Laboratorio Farmaceutico? | Similar companies to Laboratorio Farmaceutico include e.g. Agthia Group, Acomo, ForFarmers, JDE Peets. |
| What is the current market cap of Laboratorio Farmaceutico? | Laboratorio Farmaceutico's current market cap is $12.8M |
| What is the current revenue of Laboratorio Farmaceutico? | Laboratorio Farmaceutico's last 12 months revenue is $9.6M. |
| What is the current revenue growth of Laboratorio Farmaceutico? | Laboratorio Farmaceutico revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Laboratorio Farmaceutico? | Current revenue multiple of Laboratorio Farmaceutico is 1.3x. |
| Is Laboratorio Farmaceutico profitable? | Yes, Laboratorio Farmaceutico is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Laboratorio Farmaceutico? | Laboratorio Farmaceutico's last 12 months EBITDA is $2.2M. |
| What is Laboratorio Farmaceutico's EBITDA margin? | Laboratorio Farmaceutico's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Laboratorio Farmaceutico? | Current EBITDA multiple of Laboratorio Farmaceutico is 5.9x. |
| What is the current FCF of Laboratorio Farmaceutico? | Laboratorio Farmaceutico's last 12 months FCF is -$5K. |
| What is Laboratorio Farmaceutico's FCF margin? | Laboratorio Farmaceutico's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Laboratorio Farmaceutico? | Current FCF multiple of Laboratorio Farmaceutico is -2360.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
